Stocks News

LAST PRICE
76.8400
TODAY'S CHANGE (%)
Trending Down-4.8800 (-5.9716%)

Bid / Lots
40.0000/ 1
Ask / Lots
77.0000/ 1
Open / Previous Close
82.0600 / 81.7200
Day Range
Low 76.6400
High 83.8800
52 Week Range
Low 13.0500
High 86.9300
Volume
286,579
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Nov 7, 2024
- DJ Praxis Precision Med Price Target Maintained With a $120.00/Share by HC Wainwright & Co., from 8:38AM ET on Thursday Nov 07, 2024 by Dow Jones
  8:38AM ET on Thursday Nov 07, 2024 by Dow Jones
  Companies Mentioned: PRAX
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/PRAX/analyst-ratings
  
  (END) Dow Jones Newswires
  
  November 07, 2024 08:38 ET (13:38 GMT)
- DJ Praxis Precision Med Price Target Maintained With a $151.00/Share by Needham, from 4:42AM ET on Thursday Nov 07, 2024 by Dow Jones
  4:42AM ET on Thursday Nov 07, 2024 by Dow Jones
  Companies Mentioned: PRAX
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/PRAX/analyst-ratings
  
  (END) Dow Jones Newswires
  
  November 07, 2024 04:42 ET (09:42 GMT)
Nov 6, 2024
- Praxis Precision Medicines to Participate in Three Upcoming November Investor Conferences, from 5:00PM ET on Wednesday Nov 06, 2024 by Dow Jones
  5:00PM ET on Wednesday Nov 06, 2024 by Dow Jones
  Companies Mentioned: PRAX
  
  Praxis Precision Medicines to Participate in Three Upcoming November Investor Conferences
  
  BOSTON, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will be participating in three upcoming investor conferences in November 2024.
- Wedbush Raises Praxis Precision Medicines Price Target to $57 From $51, Maintains Neutral Rating, from 12:59PM ET on Wednesday Nov 06, 2024 by MT Newswires
  12:59PM ET on Wednesday Nov 06, 2024 by MT Newswires
  Companies Mentioned: PRAX
  12:59 PM EST, 11/06/2024 (MT Newswires) -- Praxis Precision Medicines (PRAX) has an average rating of Buy and price targets ranging from $51 to $270, according to analysts polled by Capital IQ. (MT Newswires covers equity, commodity and economic res...
- Praxis Precision Medicines Q3 Net Loss Widens, Collaboration Revenue Falls; Shares Drop Pre-Bell, from 8:50AM ET on Wednesday Nov 06, 2024 by MT Newswires
  8:50AM ET on Wednesday Nov 06, 2024 by MT Newswires
  Companies Mentioned: PRAX
  08:50 AM EST, 11/06/2024 (MT Newswires) -- Praxis Precision Medicines (PRAX) reported a Q3 net loss Wednesday of $2.75 per diluted share, compared with a loss of $2.72 a year earlier. Analysts polled by Capital IQ expected a loss of $1.95. Collabora...

Yesterday
- Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon, from 16 hours ago by PR Newswire
  16 hours ago by PR Newswire
  Companies Mentioned: IOVA, ONCY, SWTX, IBRX, SNDX
- Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon, from 16 hours ago by CNW Group
  16 hours ago by CNW Group
  Companies Mentioned: IOVA, ONCY, SWTX, IBRX, SNDX
Nov 12, 2024
- Day One Biopharmaceuticals Insider Sold Shares Worth $456,223, According to a Recent SEC Filing, from 5:04PM ET on Tuesday Nov 12, 2024 by MT Newswires
  5:04PM ET on Tuesday Nov 12, 2024 by MT Newswires
  Companies Mentioned: DAWN
- Rocket Pharmaceuticals to Present Updated Data from the Phase 1 Clinical Trial of RP-A501 for Danon Disease at the American Heart Association's 2024 Late-Breaking Science Sessions, from 4:01PM ET on Tuesday Nov 12, 2024 by Dow Jones
  4:01PM ET on Tuesday Nov 12, 2024 by Dow Jones
  Companies Mentioned: RCKT
- DJ Syndax Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co., from 12:28PM ET on Tuesday Nov 12, 2024 by Dow Jones
  12:28PM ET on Tuesday Nov 12, 2024 by Dow Jones
  Companies Mentioned: SNDX
- Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib, from 7:01AM ET on Tuesday Nov 12, 2024 by PR Newswire
  7:01AM ET on Tuesday Nov 12, 2024 by PR Newswire
  Companies Mentioned: SNDX
- Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib, from 7:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
  7:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
  Companies Mentioned: SNDX
Nov 11, 2024
- DJ Rocket Pharmaceuticals Is Maintained at Buy by Chardan Capital, from 5:01PM ET on Monday Nov 11, 2024 by Dow Jones
  5:01PM ET on Monday Nov 11, 2024 by Dow Jones
  Companies Mentioned: RCKT
Nov 8, 2024
- Rocket Pharmaceuticals to Participate in the UBS Global Healthcare Conference, from 7:00AM ET on Friday Nov 08, 2024 by Dow Jones
  7:00AM ET on Friday Nov 08, 2024 by Dow Jones
  Companies Mentioned: RCKT
- DJ Rocket Pharmaceuticals Price Target Maintained With a $52.00/Share by Needham, from 5:34AM ET on Friday Nov 08, 2024 by Dow Jones
  5:34AM ET on Friday Nov 08, 2024 by Dow Jones
  Companies Mentioned: RCKT

Praxis Precision Medicines Inc
NASDAQ:PRAXUnited States

Search Criteria

Nov 7, 2024

DJ Praxis Precision Med Price Target Maintained With a $120.00/Share by HC Wainwright & Co., from 8:38AM ET on Thursday Nov 07, 2024 by Dow Jones

DJ Praxis Precision Med Price Target Maintained With a $151.00/Share by Needham, from 4:42AM ET on Thursday Nov 07, 2024 by Dow Jones

Nov 6, 2024

Praxis Precision Medicines to Participate in Three Upcoming November Investor Conferences, from 5:00PM ET on Wednesday Nov 06, 2024 by Dow Jones

Wedbush Raises Praxis Precision Medicines Price Target to $57 From $51, Maintains Neutral Rating, from 12:59PM ET on Wednesday Nov 06, 2024 by MT Newswires

Praxis Precision Medicines Q3 Net Loss Widens, Collaboration Revenue Falls; Shares Drop Pre-Bell, from 8:50AM ET on Wednesday Nov 06, 2024 by MT Newswires

Peers Headlines

Yesterday

Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon, from 16 hours ago by PR Newswire

Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon, from 16 hours ago by CNW Group

Nov 12, 2024

Day One Biopharmaceuticals Insider Sold Shares Worth $456,223, According to a Recent SEC Filing, from 5:04PM ET on Tuesday Nov 12, 2024 by MT Newswires

Rocket Pharmaceuticals to Present Updated Data from the Phase 1 Clinical Trial of RP-A501 for Danon Disease at the American Heart Association's 2024 Late-Breaking Science Sessions, from 4:01PM ET on Tuesday Nov 12, 2024 by Dow Jones

DJ Syndax Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co., from 12:28PM ET on Tuesday Nov 12, 2024 by Dow Jones

Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib, from 7:01AM ET on Tuesday Nov 12, 2024 by PR Newswire

Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib, from 7:00AM ET on Tuesday Nov 12, 2024 by Dow Jones

Nov 11, 2024

DJ Rocket Pharmaceuticals Is Maintained at Buy by Chardan Capital, from 5:01PM ET on Monday Nov 11, 2024 by Dow Jones

Nov 8, 2024

Rocket Pharmaceuticals to Participate in the UBS Global Healthcare Conference, from 7:00AM ET on Friday Nov 08, 2024 by Dow Jones

DJ Rocket Pharmaceuticals Price Target Maintained With a $52.00/Share by Needham, from 5:34AM ET on Friday Nov 08, 2024 by Dow Jones